Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Kalunian

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Rheumatology (Oxford, England)|December 1, 2020
Arthroscopy in rheumatology: where have we been? Where might we go?Robert W Ike, William J Arnold, Kenneth C Kalunian
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|November 20, 2023
What Bedside Skills Could the Modern Rheumatologist Possess? Part II. "Certain Technical Procedures"Robert W Ike, Sara S McCoy, Kenneth C Kalunian
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 9, 2023
What Bedside Skills Could the Modern Rheumatologist Possess? Part I. The BasicsRobert W Ike, Sara S McCoy, Kenneth C Kalunian
Arthritis and Rheumatism|August 12, 2011
CXCL13 as a marker for outcome of rheumatoid arthritis: comment on the article by Meeuwisse et alSanna Rosengren, Kenneth C Kalunian, Arthur Kavanaugh, et al.
Rheumatology (Oxford, England)|November 25, 2010
CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritisSanna Rosengren, Nathan Wei, Kenneth C Kalunian, et al.
Arthritis and Rheumatism|December 17, 2002
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trialKenneth C Kalunian, John C Davis, Joan T Merrill, et al.
Arthritis Research & Therapy|September 3, 2008
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximabSanna Rosengren, Nathan Wei, Kenneth C Kalunian, et al.
Annals of the Rheumatic Diseases|March 23, 2018
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trialJoan T Merrill, William R Shanahan, Morton Scheinberg, et al.
The Journal of Rheumatology|January 19, 2010
Inflammatory characteristics on ultrasound predict poorer longterm response to intraarticular corticosteroid injections in knee osteoarthritisJeannie Chao, Christopher Wu, Bob Sun, et al.
The Journal of Rheumatology|December 1, 2004
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics groupSean J Wollaston, Vernon T Farewell, David A Isenberg, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Rheumatology (Oxford, England)|December 1, 2020
Arthroscopy in rheumatology: where have we been? Where might we go?Robert W Ike, William J Arnold, Kenneth C Kalunian
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|November 20, 2023
What Bedside Skills Could the Modern Rheumatologist Possess? Part II. "Certain Technical Procedures"Robert W Ike, Sara S McCoy, Kenneth C Kalunian
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 9, 2023
What Bedside Skills Could the Modern Rheumatologist Possess? Part I. The BasicsRobert W Ike, Sara S McCoy, Kenneth C Kalunian
Arthritis and Rheumatism|August 12, 2011
CXCL13 as a marker for outcome of rheumatoid arthritis: comment on the article by Meeuwisse et alSanna Rosengren, Kenneth C Kalunian, Arthur Kavanaugh, et al.
Rheumatology (Oxford, England)|November 25, 2010
CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritisSanna Rosengren, Nathan Wei, Kenneth C Kalunian, et al.
Arthritis and Rheumatism|December 17, 2002
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trialKenneth C Kalunian, John C Davis, Joan T Merrill, et al.
Arthritis Research & Therapy|September 3, 2008
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximabSanna Rosengren, Nathan Wei, Kenneth C Kalunian, et al.
Annals of the Rheumatic Diseases|March 23, 2018
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trialJoan T Merrill, William R Shanahan, Morton Scheinberg, et al.
The Journal of Rheumatology|January 19, 2010
Inflammatory characteristics on ultrasound predict poorer longterm response to intraarticular corticosteroid injections in knee osteoarthritisJeannie Chao, Christopher Wu, Bob Sun, et al.
The Journal of Rheumatology|December 1, 2004
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics groupSean J Wollaston, Vernon T Farewell, David A Isenberg, et al.
Pageof 9